查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046060

肺氣腫治療市場－全球產業規模、佔有率、趨勢、機會、預測：治療方法、通路、終端用戶、地區及競爭格局，2021-2031年

Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Distribution Channel, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肺氣腫治療市場預計將從 2025 年的 45.4 億美元大幅成長至 2031 年的 64.9 億美元，複合年成長率為 6.14%。

該市場專注於肺泡破壞的治療，旨在透過各種治療方法改善呼吸功能，包括支氣管擴張劑和皮質類固醇等藥物療法以及肺部減容手術。推動這一市場成長的主要因素包括全球吸菸率上升、持續暴露於環境污染物以及老年人口不斷成長（老年人尤其容易出現進行性呼吸功能衰退）。這些因素共同作用，使得人們對有效治療策略的需求持續存在，而這種需求與藥物傳遞技術的進步無關。

市場概覽
預測期 2027-2031
市場規模：2025年 45.4億美元
市場規模：2031年 64.9億美元
複合年成長率：2026-2031年 6.14%
成長最快的細分市場 門診手術中心
最大的市場 北美洲

然而，這個市場面臨許多挑戰。主要因素包括先進治療方法的高昂成本以及嚴格的監管要求，這些都常常延緩新治療方法的上市進程。慢性阻塞性肺病基金會在其2025年報告中估計，美國有超過3000萬人患有慢性阻塞性肺病（COPD），並指出相當一部分病例尚未確診，因此迫切需要便捷有效的治療性介入。

市場促進因素

新型生物製藥和三重聯合治療的出現正在徹底改變市場格局，這些療法針對特定發炎通路，超越了傳統支氣管擴張劑的治療範圍。近期監管部門的核准為磷酸二酯酶抑制劑和作用於2型發炎的治療方法鋪平了道路，為頻繁急性發作且症狀中重度的患者帶來了顯著益處。這種治療模式轉移得益於其快速的市場滲透。例如，Verona Pharma於2025年4月發布的報告顯示，其近期推出的維持治療藥物Ohtuvayre在2025年第一季的淨銷售額達到了7,130萬美元。鑑於因持續暴露於環境污染物而需要更先進醫療服務的人口不斷成長，此類創新變得日益重要。美國肺臟協會估計，到2025年，將有1.56億美國人生活在空氣品質不符合標準的地區，這將推動對有效呼吸系統干預措施的強勁需求。

同時，微創肺減容術（LVR）技術的日益普及是另一個重要的市場促進因素。對於僅靠藥物治療效果不佳的重度肺氣腫患者，此趨勢尤其顯著。由於恢復時間較短，且能有效阻斷受累肺區並改善呼吸功能，支氣管內瓣膜正逐漸取代高創傷性外科治療方法，成為更受歡迎的選擇。隨著全球醫療系統採用推薦使用這些治療設備的最新治療方案，該領域正經歷強勁成長。例如，Pulmonx公司在其2025年11月發布的2025年第三季財報中披露，其全球銷售額達2150萬美元，並重點介紹了其Zephyr瓣膜系統在治療重度肺氣腫方面日益廣泛的國際應用。

市場挑戰

全球肺氣腫治療市場面臨的主要障礙是先進治療方法的高昂費用和嚴格的監管要求。這些財務和程序上的障礙直接阻礙了市場擴張，限制了患者獲得必要治療的機會，並延緩了新產品的上市。先進的藥物療法和肺部減容手術通常價格昂貴，給缺乏完善醫療體系或保險的個人帶來沉重的經濟負擔。這導致在對成本敏感的地區，這些療法的普及率較低，從而限制了製造商的潛在收入成長。此外，嚴格的法規環境要求大量的資本投入和漫長的臨床試驗週期，增加了開發創新療法的公司的財務風險。

呼吸系統疾病對生產力造成的廣泛經濟影響進一步凸顯了這一經濟負擔。世界衛生組織（世衛組織）和歐洲呼吸學會（ERS）共同發布的2025年報告顯示，慢性呼吸道疾病造成的區域生產力損失約207億美元。這項數據凸顯了治療機會有限所帶來的嚴重經濟後果。持續高成本和監管壁壘是限制肺氣腫盛行率上升的瓶頸，阻礙了人們充分利用不斷成長的市場需求，從而有效地抑制了經濟成長。

市場趨勢

機器人輔助支氣管鏡系統從根本上改變了肺氣腫的治療方法，使醫生能夠精準地進入以往傳統技術無法觸及的肺部周邊區域。這些先進的機器人系統採用形狀感知技術和超細導管，提高了穩定性，並能夠深入周邊氣道。這使得肺科醫生能夠以顯著更高的準確性和安全性進行切片檢查和治療。對於肺部結構受損的肺氣腫患者而言，這項技術尤其重要，它能大幅降低經皮抽吸術相關的氣胸風險，即使在困難病例中也能實現早期介入。這些自動化引導工具在臨床實踐中的快速普及表明了其強大的市場支持。據直覺外科公司（Intuitive Surgical）稱，2025年4月使用Ion系統的手術數量同比成長58%，顯示機器人輔助呼吸介入治療的應用顯著擴展。

同時，遠端數位呼吸監測解決方案的採用正在革新肺氣腫的長期管理，將治療模式從被動的急性期治療模式轉變為居家環境下持續的、數據驅動的支持模式。這些數位平台整合了雲端連接的治療設備，能夠密切監測氣流、治療依從性和漏氣率等關鍵參數，並將即時數據傳輸給醫療專業人員，以預防病情加重。這種互聯互通的方法不僅降低了再入院率，還透過減少現場就診次數提高了資源利用效率，使臨床醫生能夠遠端調整治療方案。這一數位健康模式的商業性成功得益於領先醫療設備製造商銷售額的成長。例如，瑞思邁公司（ResMed Inc.）的住宅護理軟體部門報告稱，截至2025年8月，銷售額達6.414億美元，年增10%，這表明呼吸健康管理領域對整合軟體解決方案的依賴性日益增強。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肺氣腫治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（戒菸療法、支氣管擴張劑、類固醇、白三烯拮抗劑、氧氣治療、抗生素、基因療法、手術/移植、其他治療方法）
    • 分銷管道（醫院藥房、零售藥房、其他分銷管道）
    • 依最終使用者（醫院/診所、門診手術中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肺氣腫治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肺氣腫治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肺氣腫治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肺氣腫治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肺氣腫治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肺氣腫治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Icure Pharmaceuticals Inc.
  • AstraZeneca Plc.
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Hikma Pharmaceuticals Plc
  • Boehringer Ingelheim International GmbH
  • Mylan NV
  • Pfizer Inc.
  • Orion Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17479

The global market for emphysema treatment is projected to expand significantly, increasing from USD 4.54 Billion in 2025 to USD 6.49 Billion by 2031, demonstrating a compound annual growth rate of 6.14%. This market addresses the management of alveolar destruction and aims to enhance respiratory function through various therapeutic approaches, which include pharmacological options like bronchodilators and corticosteroids, as well as lung volume reduction procedures. A major impetus for this growth stems from the rising worldwide incidence of tobacco smoking, ongoing exposure to environmental pollutants, and a growing elderly population that is particularly vulnerable to progressive respiratory decline. These elements collectively fuel a sustained need for effective treatment strategies, independent of advancements in drug delivery technology.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.54 Billion
Market Size 2031USD 6.49 Billion
CAGR 2026-20316.14%
Fastest Growing SegmentAmbulatory Surgical Centers
Largest MarketNorth America

Nevertheless, the market encounters substantial obstacles, primarily due to the elevated costs associated with advanced therapeutic options and strict regulatory demands that frequently postpone the market entry of new treatments. The COPD Foundation reported in 2025 that over 30 million individuals in the United States were estimated to be affected by chronic obstructive pulmonary disease, highlighting a considerable, though frequently undiagnosed, patient population in urgent need of readily available therapeutic interventions.

Market Driver

The market is being significantly transformed by the emergence of new biologics and triple-combination therapies, which target specific inflammatory pathways previously beyond the scope of conventional bronchodilator treatments. Recent regulatory approvals have paved the way for therapies that act on phosphodiesterase inhibitors and type 2 inflammation, providing substantial advantages for patients experiencing frequent exacerbations and presenting with moderate to severe conditions. This paradigm shift in treatment is underscored by swift market penetration, as exemplified by Verona Pharma's report in April 2025, which showed net product sales of $71.3 million for its recently introduced maintenance therapy, Ohtuvayre, in its First Quarter 2025 Financial Results. Such innovations are increasingly critical given that ongoing exposure to environmental pollutants continues to expand the population requiring advanced medical attention; the American Lung Association noted in 2025 that 156 million Americans resided in areas with substandard air quality, thus perpetuating the strong demand for effective respiratory interventions.

Concurrently, the increasing embrace of minimally invasive lung volume reduction (LVR) procedures serves as another key market driver, particularly for cases of severe emphysema where pharmacological interventions alone are inadequate. Endobronchial valves are gaining preference over more intrusive surgical alternatives because they offer quicker recovery periods and effectively block diseased lung segments to enhance breathing mechanics. This sector is experiencing robust growth as healthcare systems worldwide adopt updated treatment protocols that advocate for these interventional tools. For example, Pulmonx Corporation reported global revenue of $21.5 million in its Third Quarter 2025 Financial Results in November 2025, which highlights the growing international use of its Zephyr Valve system for treating severe emphysema.

Market Challenge

A significant obstacle facing the Global Emphysema Treatment Market is the prohibitive cost of advanced therapies, coupled with stringent regulatory demands. These financial and procedural hurdles directly impede market expansion by limiting patient access to essential treatments and prolonging the market entry of new products. Both sophisticated pharmacotherapies and lung volume reduction procedures are often premium-priced, imposing considerable financial strain on healthcare systems and individuals without adequate insurance. This leads to reduced adoption rates in cost-sensitive regions, thereby restricting potential revenue growth for manufacturers. Moreover, rigorous regulatory environments demand substantial capital investment and extended clinical trial periods, escalating the financial risks for companies developing innovative therapeutics.

The broader economic consequences of respiratory illnesses on productivity further illustrate this financial burden. A 2025 joint report from the World Health Organization and the European Respiratory Society indicated that the regional productivity loss due to chronic respiratory diseases was approximately US$20.7 billion. This statistic underscores the profound economic repercussions stemming from restricted access to treatment. The persistence of high costs and regulatory setbacks forms a bottleneck, hindering the market's ability to fully leverage increasing demand and effectively stifling growth, even amidst the rising prevalence of emphysema.

Market Trends

Robotic-assisted interventional bronchoscopy systems are profoundly transforming the treatment approaches for emphysema by offering precise entry into peripheral lung areas that were previously inaccessible through traditional techniques. These advanced robotic systems incorporate shape-sensing technology and extremely thin catheters, providing enhanced stability and the ability to reach deep into distal airways. This enables pulmonologists to conduct biopsies or administer treatments with significantly improved accuracy and safety. This capability is especially crucial for individuals with emphysema who have compromised lung structures, as it substantially reduces the risk of pneumothorax often linked with percutaneous needle procedures and allows for earlier intervention in challenging cases. The market's strong inclination towards these automated guidance tools is demonstrated by their swift integration into clinical practice, with Intuitive Surgical reporting a 58% increase in Ion procedures in April 2025 compared to the prior year's first quarter, signaling a substantial growth in the use of robotic respiratory interventions.

Concurrently, the deployment of remote digital respiratory monitoring solutions is revolutionizing the long-term management of emphysema, transitioning care from a reactive acute model to one of continuous, data-informed support within the home environment. These digital platforms incorporate cloud-connected therapeutic devices that diligently monitor vital parameters like airflow, treatment adherence, and leak rates, relaying real-time data to healthcare professionals to proactively prevent exacerbations. This interconnected approach not only decreases hospital readmission rates but also enhances resource efficiency by enabling clinicians to modify treatment regimens remotely, eliminating the need for in-person office visits. The commercial success of this digital health paradigm is confirmed by the increasing revenues of prominent medical device companies; ResMed Inc.'s Residential Care Software segment, for instance, reported revenue of $641.4 million in August 2025, a 10% rise from the previous fiscal year, underscoring the growing dependence on integrated software solutions for managing respiratory health.

Key Market Players

  • Icure Pharmaceuticals Inc.
  • AstraZeneca Plc.
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • GlaxoSmithKline Plc.
  • Hikma Pharmaceuticals Plc
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Pfizer Inc.
  • Orion Corporation

Report Scope

In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Emphysema Treatment Market, By Treatment

  • Smoking Cessation
  • Bronchodilators
  • Steroids
  • Leukotriene Modifiers
  • Supplemental Oxygen
  • Antibiotics
  • Gene Therapy
  • Surgery Transplant
  • Other Treatments

Emphysema Treatment Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

Emphysema Treatment Market, By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Emphysema Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Emphysema Treatment Market.

Available Customizations:

Global Emphysema Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Emphysema Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments)
    • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
    • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Emphysema Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Distribution Channel
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Emphysema Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Distribution Channel
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Emphysema Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Distribution Channel
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Emphysema Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Distribution Channel
        • 6.3.3.2.3. By End-User

7. Europe Emphysema Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Distribution Channel
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Emphysema Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Distribution Channel
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Emphysema Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Distribution Channel
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Emphysema Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Distribution Channel
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Emphysema Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Distribution Channel
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Emphysema Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Distribution Channel
        • 7.3.5.2.3. By End-User

8. Asia Pacific Emphysema Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Distribution Channel
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Emphysema Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Distribution Channel
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Emphysema Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Distribution Channel
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Emphysema Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Distribution Channel
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Emphysema Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Distribution Channel
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Emphysema Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Distribution Channel
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Emphysema Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Distribution Channel
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Emphysema Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Distribution Channel
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Emphysema Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Distribution Channel
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Emphysema Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Distribution Channel
        • 9.3.3.2.3. By End-User

10. South America Emphysema Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Distribution Channel
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Emphysema Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Distribution Channel
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Emphysema Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Distribution Channel
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Emphysema Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Distribution Channel
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Emphysema Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Icure Pharmaceuticals Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca Plc.
  • 15.3. Teva Pharmaceuticals Industries Ltd.
  • 15.4. Novartis AG
  • 15.5. GlaxoSmithKline Plc.
  • 15.6. Hikma Pharmaceuticals Plc
  • 15.7. Boehringer Ingelheim International GmbH
  • 15.8. Mylan N.V.
  • 15.9. Pfizer Inc.
  • 15.10. Orion Corporation

16. Strategic Recommendations

17. About Us & Disclaimer